SCHEMBL6497600

SCHEMBL6497600

O=C(O)CCC(O)c1ccc2c(c1)OCCO2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.55
PTGS2 P35354 1/20 0.55
AOC3 Q16853 1/20 0.55
TSHR P16473 3/20 0.54
PKM P14618 1/20 0.54
ALDH1A1 P00352 5/20 0.51
MAPT P10636 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
HSD17B10 Q99714 2/20 0.51
HTT P42858 2/20 0.51
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
CASP1 P29466 1/20 0.51
MAPK1 P28482 2/20 0.47
TP53 P04637 1/20 0.47
CTNNB1 P35222 1/20 0.46
KDM4E B2RXH2 2/20 0.44
HPGD P15428 3/20 0.43
RAB9A P51151 1/20 0.43
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22478570 0.84 PTGS1 (0.58) PTGS1PTGS2AOC3TSHRPKM
SCHEMBL3147826 0.84 HDAC3 (0.53) AOC3TSHRPKMALDH1A1MAPT
SCHEMBL5491732 0.81 AOC3 (0.65) PTGS1PTGS2AOC3SMN1; SMN2HSD17B10
SCHEMBL3183717 0.81 AOC3 (0.60) PTGS1PTGS2AOC3TSHRMAPT
SCHEMBL21441366 0.80 CTNNB1 (0.63) PTGS1PTGS2AOC3PKMSMN1; SMN2
SCHEMBL5207237 0.80 AOC3 (0.59) PTGS1PTGS2AOC3TSHRMAPT
SCHEMBL27617494 0.80 AOC3 (0.59) PTGS1PTGS2AOC3TSHRPKM
SCHEMBL22785898 0.77 AOC3 (0.64) PTGS1PTGS2AOC3TSHRHTT
SCHEMBL22785949 0.77 AOC3 (0.64) PTGS1PTGS2AOC3TSHRHTT
SCHEMBL20379845 0.76 PTGS1 (0.59) PTGS1PTGS2AOC3TSHRPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113366-A1 Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of $g(g)-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses UNIVERSITE LOUIS PASTEUR (ETABLISSEMENT PUBLIC A CARACTERE SCIENTIFIQUE, CULTUREL ET PROFESSIONNEL) (FR) 2005-05-26 US claimed
US-20050113366-A1 Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of $g(g)-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses UNIVERSITE LOUIS PASTEUR (ETABLISSEMENT PUBLIC A CARACTERE SCIENTIFIQUE, CULTUREL ET PROFESSIONNEL) (FR) 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113366-A1 Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of $g(g)-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses GABRB1, GABRA1, GABRA5 PTGS1 795/4885PTGS2 1271/4885AOC3 2236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.